JJDC invested in Prazer Therapeutics, a targeted protein degradation company.
MAR 2025
Seoul-based biotechnology company developing orally available, brain-penetrating small-molecule therapeutics using its proprietary SPiDEM targeted protein degradation platform
Seoul-based biotechnology company developing orally available, brain-penetrating small-molecule therapeutics using its proprietary SPiDEM targeted protein degradation platform. Its programs target difficult-to-drug proteins across neurodegenerative diseases, oncology, and inflammatory and autoimmune conditions.